Ignite Creation Date:
2024-05-06 @ 1:49 AM
Last Modification Date:
2024-10-26 @ 11:10 AM
Study NCT ID:
NCT01909453
Status:
COMPLETED
Last Update Posted:
2024-04-26
First Post:
2013-07-24
Brief Title:
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
CMEK162B2301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None